Results

Risk Factor Profile
A total of 2,892 patients (2,028 men, 864 women; mean age, 70.3 years) with AF comprised the study group. Numbers of patients and their mean age in the 3 categories were as follows: AF category, 1,543 men (68.9±9.6 years old) and 699 women (72.4±8.5); stroke category, 399 men (70.6±8.4) and 141 women (73.0±8.3); MI category, 86 men (71.7±8.1) and 24 women (75.3±8.0). Their clinical characteristics are summarized in Table 1 . Some of the characteristics exhibited differences by sex. Women were older (P<0.001), and more frequently had congestive heart failure (P<0.001), hypertension (P=0.051), valvular diseases or valve replacement (P<0.001), and hypercholesterolemia (P<0.001) than the men, but drank (P<0.001) and smoked (P<0.001) less frequently than men. The proportion of subjects aged 75 years or older was higher and body mass index was slightly but significantly lower in women than in men (P<0.001, each case). The prevalences of chronic AF, diabetes mellitus, MI, and ischemic stroke did not differ between men and women.
The CHADS2 score was slightly but significantly higher in women than in men (Table 1, P<0.001) because of their higher prevalence of older age (≥75 years), hypertension, and congestive heart failure. The distribution of CHADS2 scores differed significantly between men and women (Table 2, P<0.001). It increased with age for both men and women, but did not differ between men and women in any age group (Table 3) .
Medications
Medications are summarized in Table 4 . Use of warfarin and antiplatelet agents did not differ between men and women. Reflecting the differences in prevalence of hypertension and hypercholesterolemia between men and women, drugs for the treatment of these diseases were used more frequently in women than in men (P<0.001, each case). In contrast, use of antidiabetic drugs was similar in men and women.
There were no apparent sex-related differences in the rate of use of warfarin or aspirin at any CHADS2 score ( Table 5) . Data are mean ± SD.
INOUE H et al.
Warfarin usage differed significantly among CHADS2 scores in both men (P<0.001) and women (P=0.001). It increased gradually from approximately 60% to 80% as the score increased from 0 to 3 for both men and women; thereafter it reached a plateau, except in the case of women with a score of 6. Aspirin usage also differed significantly among CHADS2 scores in men (P=0.008), but not in women (P=0.852). It did not show any apparent score-dependent increase as observed in the case of warfarin usage.
Discussion
The major findings of the present study are as follows. First, there were sex-related differences in the risk factor profile and medications of patients with AF recruited in J-TRACE. Women were older and more frequently had hypertension, valvular diseases, congestive heart failure, and hypercholesterolemia than men. The prevalence of diabetes mellitus, ischemic stroke, and MI did not differ between men and women. Second, CHADS2 score was consequently slightly but significantly higher in women than in men with AF. This sex-related difference could be largely related to the higher proportion of women aged 75 years or older. Third, no sexrelated differences in the use of warfarin or aspirin were observed at any CHADS2 score.
Risk Factor Profile of Patients With AF
Reports from Western countries 6-10 suggest that sex-related differences could exist in the risk factors for cardiovascular diseases of patients with AF. In the present study, mean age was higher and the prevalence of hypertension also tended to be higher in women than in men, consistent with the previous reports; 6-9 however, the prevalence of congestive heart failure was also higher in women than in men in the present study, a finding that is inconsistent with those reports from Western countries. 6-9 Notably, the prevalence of diabetes mellitus and of a prior history of ischemic stroke were not consistent. 6-9 Cohort studies of the general population in Japan have indicated that the prevalences of hypertension and diabetes mellitus are higher in men than in women. 19-21 The prevalence of cardiac diseases was not higher in women than in men with AF, 4,5 so the higher prevalences of hypertension and congestive heart failure in women with AF found in the present study do not simply reflect the prevalence of these diseases in the general population of Japan. Valvular disease is a well-known risk factor for AF, 22 especially for Japanese women. 23 Drinking and smoking could promote the development of AF, 22-25 and were present more frequently in men than in women in the present study, as in the general population of Japan. 4,5,19-21 The electrophysiological properties of the atria differ between men and women, 26 so greater comorbidity and age might be required for AF to develop in women than in men.
Thromboembolic Risk
A sex difference in CHADS2 score was found in the present study, a finding consistent with the ATRIA study. 7 In the Euro Heart Survey the score might have been higher in women than in men, because mean age and the prevalences of hypertension, diabetes mellitus, and prior ischemic stroke were significantly higher in women than in men. 9 In some studies the levels of biomarkers of a prothrombotic state were higher in women with AF than in men with AF. 27, 28 These findings could explain the inclusion of female sex as a risk factor in some schemes for predicting thromboembolic events in patients with AF. 13, 14 In fact, among patients with acute stroke, embolic infarction is observed more frequently in women than in men. 29 It is difficult to determine the reasons for the sex-related difference in thromboembolic risk; however, some components of the CHADS2 score were observed more frequently in women in the ATRIA study, 7 Euro Heart Survey, 9 and in the present study.
Medications
Registry studies in Western countries have indicated that warfarin usage does not differ between men and women. 6, 9 In the present study, the rate of warfarin usage did not differ between men and women as a whole nor did it differ between them at any CAHDS2 score ( Table 5) . Warfarin usage is at present not necessarily less frequent in women than in men, as reported in earlier registry 6 and community-based cohort 30 studies.
Use of aspirin and antidiabetic drugs was similar in men and women; however, drugs for hypertension and hypercholesterolemia were used more frequently by women than by men. The latter finding might reflect the sex-related differ- Sex Differences in AF ences in the prevalence of these diseases in the present study.
Study Limitations
First, enrollment of consecutive patients with stroke, MI, and AF was recommended, but may not necessarily have occurred at each participating site and this possible selection bias could have affected the present results. Second, data for subjects with AF were collected from 3 categories of J-TRACE, 17,18 possibly resulting in increased prevalences of ischemic stroke and MI. However, this might not necessarily have affected sex-related differences in the frequency of these diseases in the present study. Actually, when only patients of AF category were analyzed, the results did not differ in terms of sex-related differences in mean age, CHADS2 score, and prevalences of heart failure, hypertension, smoking, drinking habit and warfarin usage (data not shown). Third, the study design of the J-TRACE did not define the diagnostic criteria of comorbidities, including hypertension, hypercholesterolemia and others; however, data of comorbidities were collected from the medical record. If strict diagnostic criteria of comorbidities were used, the present results would not have changed greatly. Finally, the intensity of anticoagulation was not determined systematically, and follow-up data are not yet available.
Clinical Implications
Our findings indicate sex-related differences in the clinical risk factor profile of patients with AF, with the CHADS2 score slightly but significantly higher in women with AF than in men with AF in the clinical setting in Japan. Further follow-up studies are required to elucidate the effects of these sex-related differences on subsequent thromboembolic events.
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